Selenium

Probably not, unless you have a specific indication. Selenium has a narrower therapeutic window than most foundational nutrients, with a meaningful U-shaped dose-response: deficiency causes clear harm (Keshan disease, Kashin-Beck disease, immune dysfunction), but excess also causes harm (selenosis, possibly increased type 2 diabetes risk per Stranges et al. PMID 17712147). Most American adults consume 80-150 mcg selenium daily from typical diverse omnivorous diets, meeting or exceeding the RDA of 55 mcg. Routine supplementation in already-replete populations did not prevent cancer in the large SELECT trial (Lippman PMID 19066370) and may modestly increase diabetes risk. Clinical indications that justify supplementation include: autoimmune thyroid disease (Hashimoto's, Graves'), documented serum selenium <80 ng/mL, male subfertility as part of antioxidant stack, specific regional dietary insufficiency, or malabsorption syndromes. For healthy adults without specific indications, dietary optimization (diverse diet, occasional Brazil nut, regular seafood) is a better strategy than chronic supplementation.

It may reduce your anti-TPO antibody titers and provide some protection against thyrocyte oxidative damage, but whether it prevents progression to hypothyroidism is less certain. The evidence base is the strongest for any selenium supplementation indication. Gärtner et al. (PMID 11932302) published the seminal 2002 RCT showing sodium selenite 200 mcg/day reduced anti-TPO titers by 49% versus 10% in placebo at 3 months. Toulis et al. (PMID 20810537) meta-analysis of 4 trials with 463 participants confirmed the anti-TPO reduction. Drutel's 2013 review (PMID 23627770) addressed the open question of whether antibody reduction translates to preserved thyroid function, finding the evidence is less conclusive on hard endpoints. Mechanistically, selenium supports glutathione peroxidase and thioredoxin reductase that protect thyrocytes from the substantial oxidative stress inherent in thyroid hormone synthesis (iodide oxidation generates H₂O₂). Practical recommendation: L-selenomethionine 200 mcg daily for minimum 6 months, ideally continued indefinitely, with periodic monitoring of TSH, FT4, and anti-TPO. Selenium is an adjunct to, not replacement for, standard thyroid care—levothyroxine if hypothyroid, endocrinology follow-up, and addressing other relevant factors (vitamin D, iodine status, gluten sensitivity in some patients).

Either works; don't do both routinely. Brazil nuts are the most selenium-concentrated food, with 50-550 mcg per nut depending on soil source of the tree. A single Brazil nut daily typically provides 50-100 mcg selenium, meeting or exceeding the RDA without supplementation. Multiple Brazil nuts daily (3-5) plus a 200 mcg supplement can easily exceed the tolerable upper intake level (400 mcg/day) and risk selenosis over time. Pick one approach: Brazil nuts OR selenium supplement, not both simultaneously for sustained periods. For precision dosing (e.g., Hashimoto's therapeutic dose), supplementation is preferred because Brazil nut selenium content is so variable. For general dietary optimization without specific clinical indication, 1 Brazil nut daily is a reasonable non-supplement strategy. Other good food sources: tuna, sardines, shrimp, halibut (20-70 mcg per 3 oz serving), organ meats, eggs, whole grains. A diverse diet including 2-3 seafood servings weekly and some of these other foods typically delivers adequate selenium without dedicated supplementation.

For chronic supplementation, L-selenomethionine (often delivered as selenized yeast, e.g., SelenoPrecise) is the most evidence-based choice: high bioavailability, incorporated into tissue proteins for steady release, used in most modern clinical trials (CATALYST, many Hashimoto's trials), gentle GI profile. Sodium selenite is an older inorganic form used in earlier trials; effective for short-term repletion but less preferred for chronic use due to shorter action, less favorable safety margin, and potential pro-oxidant character at high doses. Also avoid taking selenite simultaneously with large vitamin C doses (vitamin C reduces selenite to poorly-bioavailable elemental selenium; not a concern for selenomethionine). Methylselenocysteine is of research interest for cancer biology but rarely available in consumer supplements. Practical recommendation: L-selenomethionine 100-200 mcg daily, or selenized yeast containing primarily selenomethionine. Standard doses: 100 mcg for general repletion or maintenance, 200 mcg for specific therapeutic indications like autoimmune thyroid disease.

Serum selenium test is the most accessible measure. Reference range 80-165 ng/mL; optimal 120-150 ng/mL. Serum selenium <80 ng/mL suggests suboptimal status; <60 ng/mL is meaningful deficiency. Plasma selenoprotein P (SELENOP) is a more sensitive marker of selenoprotein expression, saturating at intakes near 100-110 mcg/day—this is a research-grade test, less commonly available clinically. Risk factors for deficiency include: limited dietary diversity, strict vegetarian/vegan diet without supplementation, inflammatory bowel disease, post-bariatric surgery, chronic kidney disease on dialysis, HIV infection, living in historically low-selenium soil regions (some parts of China, New Zealand, certain European countries), and malnutrition. Symptoms of severe deficiency include fatigue, increased susceptibility to infections, hypothyroidism signs (low T3 syndrome from impaired T4→T3 conversion), possible cognitive effects, and rarely Keshan-type cardiomyopathy in extreme deficiency. Subclinical suboptimal status is often asymptomatic. Practical approach: if you have any risk factors or specific clinical indications, test; if you're a healthy adult with diverse diet, testing is typically unnecessary unless you're considering chronic supplementation.

Yes, and selenium is one of the trace minerals where excess is a real concern, unlike magnesium or vitamin C where excess is mostly a GI tolerance issue. Chronic intake above 400 mcg/day (the tolerable upper limit) can produce selenosis: hair loss and brittleness, nail changes (whitening, thickening, shedding), characteristic garlic-like breath odor, peripheral neuropathy, fatigue, skin rashes, nausea. Selenosis is generally reversible with dose reduction over weeks to months. Acute overdose (rare with supplements; more common with industrial exposure) causes severe vomiting, hypotension, pulmonary edema, and cardiac arrhythmias. Long-term supplementation at 200 mcg/day in replete populations showed a concerning signal of increased type 2 diabetes incidence in the NPC follow-up (Stranges et al., PMID 17712147). Practical implications: (1) don't combine multiple daily Brazil nuts with a 200 mcg supplement, (2) don't take selenium routinely without specific indication, (3) periodically monitor serum selenium if on chronic supplementation, keeping it in 120-150 ng/mL range, (4) watch for warning signs like nail changes or garlic breath and discontinue if they appear, (5) stay below 400 mcg/day total intake from all sources.

Not in selenium-replete populations. The story evolved as follows: the NPC trial (Clark et al., PMID 9701148) in 1996 initially suggested 200 mcg/day selenized yeast reduced total cancer mortality by ~50% in a high-risk population. This triggered enormous interest in selenium chemoprevention. However: (1) longer follow-up of NPC diluted the initial signal; (2) subgroup analysis showed benefit concentrated in participants with lowest baseline selenium and absent in higher-selenium subgroups; and (3) the much larger SELECT trial (Lippman et al., PMID 19066370) randomized 35,533 men to selenium, vitamin E, both, or placebo for prostate cancer prevention and found NO benefit from selenium. Post-SELECT consensus: selenium supplementation does not prevent cancer in selenium-replete populations. For specifically deficient populations, selenium repletion may still offer some cancer-protective effect, but routine high-dose supplementation for cancer prevention in replete populations is no longer supported and may carry modest risks (type 2 diabetes signal). For active cancer patients, selenium as adjunct to conventional therapy should be discussed with oncology—not undertaken as self-directed alternative treatment.

As part of an antioxidant combination, modest improvements are seen in sperm parameters; selenium monotherapy effects are smaller. Selenium plays specific roles in spermatogenesis: GPX4 is essential for sperm mitochondrial capsule formation; selenium is concentrated in testis via SELENOP/ApoER2 delivery. Observational studies associate low selenium with subfertility markers. Supplementation trials, usually combining selenium with vitamin E, zinc, CoQ10, L-carnitine, and folate, show modest improvements in sperm concentration, motility, and morphology in some meta-analyses (Buhling and others). Selenium alone at 100-200 mcg is less robustly effective than combination protocols. Typical male fertility antioxidant stack: selenium 100-200 mcg + vitamin E 400 IU mixed tocopherols + zinc 25 mg + L-carnitine 2 g + CoQ10 200 mg + folate 400-800 mcg, continued for minimum 3-6 months (one spermatogenesis cycle). This is adjunct to, not replacement for, urological/reproductive endocrinology evaluation of underlying causes. Baseline semen analysis, FSH, LH, testosterone, and other relevant workup should guide individualized management.

At standard doses and within total intake limits, yes. Selenium is essential for fetal development, and severe maternal deficiency has been associated with adverse pregnancy outcomes. The pregnancy RDA is 60 mcg/day (70 mcg lactating). Standard prenatal vitamins contain 30-70 mcg selenium, typically adequate for replete women. Additional supplementation up to 200 mcg/day is generally considered safe if indicated (e.g., autoimmune thyroid disease in pregnancy under endocrinology management). Do NOT exceed 400 mcg/day total intake from all sources during pregnancy—this includes dietary Brazil nuts and seafood, which can contribute substantially. High-dose supplementation has not shown pregnancy-specific benefits in RCTs (e.g., for preeclampsia prevention) and should not be pursued without clinical indication. Avoid combining multiple Brazil nuts with selenium supplementation in pregnancy. Routine prenatal care with a standard prenatal vitamin covers adequate selenium for most women; additional supplementation should be individualized with obstetric and endocrinology input.

Depends on indication. For short-term repletion of documented deficiency: 3-6 months to normalize serum selenium to 120-150 ng/mL range, then transition to dietary maintenance or lower-dose continuation. For autoimmune thyroid disease (Hashimoto's): minimum 6 months to evaluate anti-TPO response per meta-analyses; many clinicians continue indefinitely at 200 mcg/day with periodic monitoring. For mild Graves' orbitopathy: 6 months per CATALYST protocol (Marcocci PMID 21591944); discontinue after trial duration unless continued indication. For male fertility: minimum 3-6 months (one spermatogenesis cycle); may continue during active conception attempts. For general repletion without specific chronic indication: 3-6 months of supplementation to restore status, then reassess. Long-term chronic supplementation above 200 mcg/day in replete populations carries small risks (type 2 diabetes signal, possible selenosis) and is generally not recommended unless ongoing clinical indication. Periodic monitoring (serum selenium every 6-12 months if chronic use) is prudent. The default should be status-guided and indication-guided, not indefinite high-dose use in adults without specific reasons. When in doubt, reassess whether the original indication still applies and whether ongoing supplementation is serving a clear purpose.